Biomarkers in Tissue Samples From Older Women With Breast Cancer
NCT ID: NCT01346579
Last Updated: 2016-07-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
505 participants
OBSERVATIONAL
2011-04-30
2014-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer
NCT05982886
Biomarkers in Blood Samples From Older Breast Cancer Survivors
NCT01138345
Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831
NCT00898898
Study of Biomarkers in Tissue Samples From Patients With Breast Cancer
NCT01004796
Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer
NCT00897416
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To assess the relapse free-survival difference between patients with PIK3CA mutated and wild-type (WT) tumors and therefore validate PIK3CA mutation status as an important biomarker in women 70 years or older diagnosed with breast cancer.
OUTLINE:
Previously collected tissue samples are analyzed via mutation analysis of PIK3CA.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
laboratory biomarker analysis
Correlative sciences
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients underwent lumpectomy with negative margins and were clinically node-negative
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Alliance for Clinical Trials in Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mary Ellen Moynahan, MD
Role: STUDY_CHAIR
Memorial Sloan Kettering Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CDR0000699810
Identifier Type: REGISTRY
Identifier Source: secondary_id
CALGB-151101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.